Emergency Medicine | Page 62 of 62 | Links Medicus Content Curation & Alerts in Medicine

Cohort study: Adjunctive clindamycin may benefit beta-lactam antibiotic-treated patients with invasive beta-hemolytic streptococcal infections

10 Feb, 2021 | 01:13h | UTC

Effectiveness of adjunctive clindamycin in β-lactam antibiotic-treated patients with invasive β-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study – The Lancet Infectious Diseases (link to abstract – $ for full-text)

Commentary on Twitter

Our new study in Lancet ID 🔥🔥 showing a potential role for wider adjunctive use of clindamycin for iGAS even without next fasc or toxic shock. Utility in non-A,non-B strep questionable. Congratulations to stellar first author @Ahmed_HBabiker https://t.co/3t4FsmClWa

— Sameer Kadri (@SameerKadri12) December 15, 2020

Put to the test: use of rapid testing technologies for covid-19

10 Feb, 2021 | 01:51h | UTC

Put to the test: use of rapid testing technologies for covid-19 – The BMJ

Canadians Win Again – Syncope Score Systematic Review

9 Feb, 2021 | 01:03h | UTC

Canadians Win Again – Syncope Score Systematic Review – Journal Feed

Original study: Multivariable risk scores for predicting short‐term outcomes for emergency department patients with unexplained syncope: A systematic review – Academic Emergency Medicine

See calculator: Canadian Syncope Risk Score – MdCalc

Thrombosis and COVID-19: Controversies and (Tentative) Conclusions

9 Feb, 2021 | 01:41h | UTC

Thrombosis and COVID-19: Controversies and (Tentative) Conclusions – Clinical Infectious Diseases

Commentary on Twitter

https://twitter.com/JohnRossMD/status/1357992429824081921

Small RCT: Peginterferon lambda increases viral clearance in outpatients with COVID-19

9 Feb, 2021 | 01:36h | UTC

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial – The Lancet Respiratory Medicine

Guideline synopsis: Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy

7 Feb, 2021 | 20:55h | UTC

Management of Immunotherapy-Related Toxicities in Patients Treated With Immune Checkpoint Inhibitor Therapy – JAMA (free for a limited period)

Audio Clinical Review: Management of Immunotherapy-Related Toxicities

Original guideline and other resources: NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities

Prospective validation of Canadian TIA Score for subsequent stroke risk after transient ischemic attack

7 Feb, 2021 | 20:54h | UTC

Prospective validation of Canadian TIA Score and comparison with ABCD2 and ABCD2i for subsequent stroke risk after transient ischaemic attack: multicentre prospective cohort study – The BMJ

See calculator: Canadian TIA Score

Commentary on Twitter

Jeff Perry is at it again! The ABCD2 score lacks the ability to discriminate low and high risk patients following TIA, so Perry et al. have validated the Canadian TIA Score.

Infographic and bedside calculator: https://t.co/OcbaK1aG3t

Full publication: https://t.co/wt87PKzNkO pic.twitter.com/q3QdgVxp6x

— EM Ottawa (@emergmedottawa) February 4, 2021

What’s the risk of dying from a fast-spreading COVID-19 variant?

7 Feb, 2021 | 21:21h | UTC

What’s the risk of dying from a fast-spreading COVID-19 variant? – Nature

Original study: Increased hazard of death in community-tested cases of SARS-CoV-2 Variant of Concern 202012/01 – medRxiv

Review: “Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19

7 Feb, 2021 | 21:13h | UTC

“Silent” Presentation of Hypoxemia and Cardiorespiratory Compensation in COVID-19 – Anesthesia

Randomized trial: Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension

4 Feb, 2021 | 01:18h | UTC

Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension (LTH-1): A multicenter randomized controlled trial – EClinicalMedicine

Commentary on Twitter

Does induced hypothermia/targetted temp management improve outcomes in patients with traumatic brain injury?

Maybe or maybe not

But this trial slow to cool, not very cool, underpowered and mod rate of dropout

Prob does not answer questionhttps://t.co/UGRFmUVNV0 pic.twitter.com/c0iDqj2l2e

— Graham Nichol (@grahamnichol) January 29, 2021